Pernix Therapeutics Appoints Chief Operating Officer
HOUSTON -- March 10, 2014
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical
company, today announced the appointment of Terence Novak as Chief Operating
Mr. Novak most recently served as President of Norwich Pharma Services where
he established the company as a leader in the contract development and
manufacturing industry focused on specialty pharmaceutical companies. Mr.
Novak brings over 30 years of pharmaceutical industry experience, including 20
years in executive leadership in business development, sales, marketing and
operations. During that time, he led the creation of over 75 sales forces and
sales operations teams and managed multiple product launches. Prior to
Norwich, Mr. Novak served as President of North America and Chief Commercial
Officer at Patheon, Inc. where he was responsible for operations and global
sales and marketing. Prior industry leadership positions include President of
DSM Pharmaceuticals, Vice President at Cytogen, Executive Vice President at
Algos Pharmaceuticals, and Vice President at Innovex, a division of Quintiles,
and various sales and marketing positions at Bristol-Myers Squibb. Mr. Novak
has also served on various industry advisory boards as well as on the board of
directors at both Frontline Pharmaceuticals and Curaxis Pharmaceuticals.
“Terry will be working closely with our network of suppliers and manufacturers
to ensure that our customers continue to receive high quality products to meet
their needs. I am pleased to add an executive of Terry’s caliber to our
leadership team and I look forward to working with him again,” said Doug
Drysdale, President and CEO of Pernix.
Commenting on his appointment, Mr. Novak said, "I am very excited to be
joining Pernix and to work with Doug and the executive team to build on the
existing infrastructure and create an efficient, high quality specialty
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded pharmaceutical
products. The Company markets a portfolio of branded products, including:
CEDAX®, an antibiotic for middle ear infections and a number of treatments for
cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company
also markets SILENOR, a non-narcotic product for the treatment of insomnia.
The Company promotes its branded products to physicians through its Pernix
sales force and markets its generic portfolio through its wholly owned
subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The
Company’s wholly owned subsidiary, Pernix Manufacturing, manufactures and
packages products for the pharmaceutical industry in a wide range of dosage
forms. Founded in 1996, the Company is based in Houston, TX.
Additional information about Pernix is available on the Company’s website
Cautionary Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements including
words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,”
“anticipate,” “believe,” “seek,” “target” or similar expressions are
forward-looking statements. Because these statements reflect the Company’s
current views, expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties. Investors should
note that many factors, as more fully described under the caption "Risk
Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities
and Exchange Commission and as otherwise enumerated herein or therein, could
affect the Company’s future financial results and could cause actual results
to differ materially from those expressed in forward-looking statements
contained in the Company’s Annual Report on Form 10-K. The forward-looking
statements in this press release are qualified by these risk factors. These
are factors that, individually or in the aggregate, could cause our actual
results to differ materially from expected and historical results. The Company
assumes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or otherwise.
Pernix Therapeutics Holdings, Inc.
Doug Drysdale, 800-793-2145 ext. 7407
President and Chief Executive Officer
Press spacebar to pause and continue. Press esc to stop.